Skip to main content
SpringerLink
Log in

Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis

  • RESEARCH ARTICLE
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Background

The use of immune checkpoint inhibitors has led to an increase in randomized controlled trials exploring various first-line combination treatment regimens. With the introduction of new PD-1/PD-L1 inhibitors, there are now more clinical options available. For the first time, the AK105 monoclonal antibody Penpulimab, developed in China, was included. The AK105-302 Phase III trial studied the efficacy and safety of Penpulimab combined with chemotherapy in patients with advanced or metastatic squamous NSCLC. To determine the optimal treatment options, we conducted an updated network meta-analysis to compare the effectiveness and safety of these regimens.

Methods

The system retrieves data from Chinese and English electronic databases, Clinical Trials, and the gov Clinical Trial Registration website up to September 6, 2023. The study indirectly compared the efficacy and safety of PD-1/PD-L1 combination regimens, including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), all-grade adverse events, and above-grade III adverse events. Subgroup analyses were conducted based on programmed death ligand 1 (PD-L1) level, histological type, ECOG score, sex, and smoking history.

Results

Nineteen RCTS were included, with a total of ten thousand eight hundred patients. Penpulimab plus chemotherapy (Pen + CT) provided the best OS (HR = 0.55, 95% CI 0.38–0.81) for PD-L1 patients with non-selective advanced NSCLC. Except Nivolumab plus Ipilimumab (Niv + Ipi), other PD-1/PD-L1 combination therapies significantly extended PFS compared with CT, and Nivolumab plus Bevacizumab combined with chemotherapy (Niv + Bev + CT) (HR = 0.43, 95% CI 0.26–0.74) provided the best PFS benefit and was comparable to Pen + CT (HR = 1.0) for PFS prolongation. For ORR, except Niv + Ipi, all the other regimens significantly improved ORR compared with CT. In terms of safety, except Tor + CT, the incidence of any-grade AEs or grade ≥ 3 adverse events may be higher than those of chemotherapy. The subgroup analysis revealed that for patients with PD-L1 levels below 1%, treatment with Tor + CT resulted in the best progression-free survival (HR = 0.47, 95% CI 0.25–0.86). For patients with PD-L1 levels of 1% or higher, Sintilimab plus chemotherapy (Sin + CT) (HR = 0.56, 95% CI 0.31–0.99) and Camrelizumab plus chemotherapy (Cam + CT) (HR = 0.43, 95% CI 0.28–0.64) were associated with the best overall survival and progression-free survival, respectively. For patients with SqNSCLC, combined immunotherapy may provide greater survival benefits. For patients with Non-sqNSCLC, Niv + Bev + CT and Tor + CT were associated with optimal PFS and OS, respectively. Cam + CT provided the best PFS in male patients with a history of smoking and an ECOG score of 0. In both female and non-smoking patient subgroups, Pem + CT was associated with the best PFS and OS benefits.

Conclusion

For patients with advanced non-selective PD-L1 NSCLC, two effective regimens are Pen + CT and Niv + Bev + CT, which rank first in OS and PFS among all patients. Cam + CT and Tor + CT have advantages for OS in patients with SqNSCLC and Non-sqNSCLC, respectively. Niv + Ipi + CT provided the best OS benefit for patients with an ECOG score of 0, while Pem + CT may be the most effective treatment for patients with an ECOG score of 1. Pem + CT has a better effect on female patients and non-smokers. Sin + CT was found to be the most effective treatment for male patients and the smoking subgroup, while Cam + CT was found to be the most effective for PFS. In addition, Tor + CT was associated with the best PFS for patients with negative PD-L1 expression. Pem + CT was found to significantly improve both PFS and OS compared to CT alone. For patients with positive PD-L1 expression, Sin + CT and Cam + CT were found to be optimal for OS and PFS, respectively. It is important to note that, with the exception of Tor + CT, the toxicity of the other combinations was higher than that of CT alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond). 2021;41(10):1037–48. https://doi.org/10.1002/cac2.12197.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Kaur J, Elms J, Munn AL, Good D, Wei MQ. Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy. Crit Rev Oncol Hematol. 2021;164:103417. https://doi.org/10.1016/j.critrevonc.2021.103417.

    Article  PubMed  Google Scholar 

  3. Zhou C, Wang J, Wang B, Cheng Y, Wang Z, Han B, et al. Chinese experts consensus on immune checkpoint inhibitors for non-small cell lung cancer (2020 version)]. Zhongguo Fei Ai Za Zhi. 2021;24(4):217–35. https://doi.org/10.3779/j.issn.1009-3419.2021.101.13.

    Article  PubMed  Google Scholar 

  4. Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun (Lond). 2022;42(10):937–70. https://doi.org/10.1002/cac2.12359.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Judd J, Borghaei H. Combining immunotherapy and chemotherapy for non-small cell lung cancer. Thorac Surg Clin. 2020;30(2):199–206. https://doi.org/10.1016/j.thorsurg.2020.01.006.

    Article  PubMed  Google Scholar 

  6. Wu X, Gu Z, Chen Y, Chen B, Chen W, Weng L, et al. Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J. 2019;17:661–74. https://doi.org/10.1016/j.csbj.2019.03.006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15(5):1111–22. https://doi.org/10.1080/21645515.2019.1571892.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Novello S, Kowalski DM, Luft A, Gümüş M, Vicente D, Mazières J, et al. Pembrolizumab Plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. J Clin Oncol. 2023;41(11):1999–2006. https://doi.org/10.1200/JCO.22.01990.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, Dómine M, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 2023;41(11):1992–8. https://doi.org/10.1200/JCO.22.01989.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130) : a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924–37. https://doi.org/10.1016/S1470-2045(19)30167-6.

    Article  CAS  PubMed  Google Scholar 

  11. Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodríguez-Abreu D, Hussein M, et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial. J Thorac Oncol. 2020;15(8):1351–60. https://doi.org/10.1016/j.jtho.2020.03.028.

    Article  CAS  PubMed  Google Scholar 

  12. National Comprehensive Cancer Network. (NCCN) Clinical practice guidelines in oncology. Non small cell lung cancer, version 3. 2023. https://www.nccn.org/profe-ssionals/physician_gls/f_guidelines.asp. Accessed 15 Sep 2023

  13. Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020;30(6):507–19. https://doi.org/10.1038/s41422-020-0337-2.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Wang Z, Wu L, Li B, Cheng Y, Li X, Wang X, et al. Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: a multicenter randomized phase III trial (CHOICE-01). J Clin Oncol. 2023;41(3):651–63. https://doi.org/10.1200/JCO.22.00727.

    Article  CAS  PubMed  Google Scholar 

  15. Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S, et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (oncology pRogram by InnovENT anti-PD-1–11). J Thorac Oncol. 2020;15(10):1636–46. https://doi.org/10.1016/j.jtho.2020.07.014.

    Article  CAS  PubMed  Google Scholar 

  16. Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen G, et al. Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12). J Thorac Oncol. 2021;16(9):1501–11. https://doi.org/10.1016/j.jtho.2021.04.011.

    Article  CAS  PubMed  Google Scholar 

  17. Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, et al. Camrelizumab plus carboplatin and pemetrexed as first-line treatment for advanced nonsquamous NSCLC: extended follow-up of camel phase 3 trial. J Thorac Oncol. 2023;18(5):628–39. https://doi.org/10.1016/j.jtho.2022.12.017.

    Article  CAS  PubMed  Google Scholar 

  18. Ren S, Chen J, Xu X, Jiang T, Cheng Y, Chen G, et al. Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (camel-sq): a phase 3 trial. J Thorac Oncol. 2022;17(4):544–57. https://doi.org/10.1016/j.jtho.2021.11.018.

    Article  CAS  PubMed  Google Scholar 

  19. Lu S, Wang J, Yu Y, Yu X, Hu Y, Ai X, et al. Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial. J Thorac Oncol. 2021;16(9):1512–22. https://doi.org/10.1016/j.jtho.2021.05.005.

    Article  CAS  PubMed  Google Scholar 

  20. Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7(5):709–17. https://doi.org/10.1001/jamaoncol.2021.0366.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Han B, Jiao S, Chen J, Wang Z, Zhao Y, Zhang G, et al. 59MO-Final analysis of AK105–302: a randomized, double-blind, placebo- controlled, phase Itrial of penpulimab plus carboplatin andpaclitaxel as first-line treatment for advanced squamous NSCLC. Immuno-Oncology and Technology. 2022;16(1): 100102. https://doi.org/10.1016/j.iotech.2022.100164.

    Article  Google Scholar 

  22. Zhou C, Wang Z, Sun M, Cao L, Ma Z, Wu R, et al. Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC. Nat Cancer. 2023;4(6):860–71. https://doi.org/10.1038/s43018-023-00578-z.

    Article  CAS  PubMed  Google Scholar 

  23. Awad MM, Gadgeel SM, Borghaei H, Patnaik A, Yang JC, Powell SF, et al. Long-term overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumabas first-line therapy for advanced nonsquamous NSCLC. J Thorac Oncol. 2021;16(1):162–8. https://doi.org/10.1016/j.jtho.2020.09.015.

    Article  CAS  PubMed  Google Scholar 

  24. Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodríguez-Abreu D, Hussein M, et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial. J Thorac Oncol. 2020;15(8):1351–60. https://doi.org/10.1016/j.jtho.2020.03.028.

    Article  CAS  PubMed  Google Scholar 

  25. Nishio M, Barlesi F, West H, Ball S, Bordoni R, Cobo M, et al. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial. J Thorac Oncol. 2021;16(4):653–64. https://doi.org/10.1016/j.jtho.2020.11.025.

    Article  CAS  PubMed  Google Scholar 

  26. Socinski MA, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J Thorac Oncol. 2021;16(11):1909–24. https://doi.org/10.1016/j.jtho.2021.07.009.

    Article  CAS  PubMed  Google Scholar 

  27. Brahmer JR, Lee JS, Ciuleanu TE, Bernabe Caro R, Nishio M, Urban L, et al. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in checkmate 227. J Clin Oncol. 2023;41(6):1200–12. https://doi.org/10.1200/JCO.22.01503.

    Article  CAS  PubMed  Google Scholar 

  28. Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198–211. https://doi.org/10.1016/S1470-2045(20)30641-0.

    Article  CAS  PubMed  Google Scholar 

  29. Sugawara S, Lee JS, Kang JH, Kim HR, Inui N, Hida T, et al. Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2021;32(29):1137–47. https://doi.org/10.1016/j.annonc.2021.06.004.

    Article  CAS  PubMed  Google Scholar 

  30. Zhang L, Wang Z, Fang J, Yu Q, Han B, Cang S, et al. Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study. Lung Cancer. 2022;171:56–60. https://doi.org/10.1016/j.lungcan.2022.07.013.

    Article  CAS  PubMed  Google Scholar 

  31. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–51. https://doi.org/10.1056/NEJMoa1810865.

    Article  CAS  PubMed  Google Scholar 

  32. Rodríguez-Abreu D, Powell SF, Hochmair MJ, Gadgeel S, Esteban E, Felip E, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021;32(7):881–95. https://doi.org/10.1016/j.annonc.2021.04.008.

    Article  CAS  PubMed  Google Scholar 

  33. Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lungcancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncol. 2022;23(2):220–33. https://doi.org/10.1016/S1470-2045(21)00650-1.

    Article  CAS  PubMed  Google Scholar 

  34. Kim HR, Sugawara S, Lee JS, Kang JH, Inui N, Hida T, et al. First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538–52/TASUKI-52 randomized controlled trial. Cancer Med. 2023;12(16):17061–7. https://doi.org/10.1002/cam4.6348.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Liu L, Bai H, Wang C, Seery S, Wang Z, Duan J, et al. Efficacy and safety of first-line immunotherapy combinations for advanced NSCLC: a systematic review and network meta-analysis. J Thorac Oncol. 2021;16(7):1099–117. https://doi.org/10.1016/j.jtho.2021.03.016.

    Article  CAS  PubMed  Google Scholar 

  36. Wang L, Yang Y, Yu J, Zhang S, Li X, Wu X, et al. Efficacy and safety of anti-PD-1/PD-L1 in combination with chemotherapy or not as first-line treatment for advanced non-small cell lung cancer: a systematic review and network meta-analysis. Thorac Cancer. 2022;13(3):322–37. https://doi.org/10.1111/1759-7714.14244.

    Article  CAS  PubMed  Google Scholar 

  37. Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384–91. https://doi.org/10.1172/JCI80011.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res. 2017;23(12):3158–67. https://doi.org/10.1158/1078-0432.

    Article  CAS  PubMed  Google Scholar 

  39. Zhao M, Shao T, Ren Y, Zhou C, Tang W. Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: updated systematic review and network meta-analysis. Front Pharmacol. 2022;13:910656. https://doi.org/10.3389/fphar.2022.910656.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Shao J, Wang C, Ren P, Jiang Y, Tian P, Li W. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer. Biosci Rep. 2020;40(5):20192347. https://doi.org/10.1042/BSR20192347.

    Article  Google Scholar 

  41. Mohammed N, Xiao EH, Mohsen S, Xiong Z, Zhou R. PD-1/PD-L1 inhibitor treatment and its impact on clinical imaging in non-small cell lung cancer: a systematic review and meta-analysis of immune-related adverse events. Front Oncol. 2023;13:1191681. https://doi.org/10.3389/fonc.2023.1191681.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Wang Z, Zhao J, Ma Z, Cui J, Shu Y, Liu Z, et al. A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in chinese patients. Lung Cancer. 2020;147:259–68. https://doi.org/10.1016/j.lungcan.2020.06.007.

    Article  PubMed  Google Scholar 

  43. Yang JJ, Huang C, Fan Y, Pan H, Feng J, Jiang L, et al. Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study. Cancer Immunol Immunother. 2022;71(6):1393–402. https://doi.org/10.1007/s00262-021-03091-3.

    Article  CAS  PubMed  Google Scholar 

  44. Pérez-Ruiz E, Melero I, Kopecka J, Sarmento-Ribeiro AB, García-Aranda M, De Las RJ. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. Drug Resist Updat. 2020;53:100718. https://doi.org/10.1016/j.drup.2020.100718.

    Article  PubMed  Google Scholar 

  45. Lu Y, Zhang X, Ning J, Zhang M. Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: a systematic evaluation and meta-analysis. Hum Vaccin Immunother. 2023;19(1):2169531. https://doi.org/10.1080/21645515.2023.2169531.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Siciliano MA, Caridà G, Ciliberto D, d’Apolito M, Pelaia C, Caracciolo D, et al. Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis. ESMO Open. 2022;7(3):100465. https://doi.org/10.1016/j.esmoop.2022.100465.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Mo DC, Huang JF, Luo PH, Huang SX, Wang HL. The efficacy and safety of combination therapy with immune checkpoint inhibitors in non-small cell lung cancer: A meta-analysis. Int Immunopharmacol. 2021;96:107594. https://doi.org/10.1016/j.intimp.2021.107594.

    Article  CAS  PubMed  Google Scholar 

  48. Peng TR, Lin HH, Tsai FP, Wu TW. Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: a systematic review and network meta-analysis. Thorac Cancer. 2021;12(21):2873–85. https://doi.org/10.1111/1759-7714.14148.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Liu T, Wu S, Fang W, Li H, Su L, Qi G, et al. Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: a systematic review and network meta-analysis. PLoS ONE. 2023;18(4):e0283719. https://doi.org/10.1371/journal.pone.0283719.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Huang Z, Pang X, Zhong T, Qu T, Chen N, Ma S, et al. Penpulimab, an fc-engineered igG1 anti-PD-1 antibody, with improved efficacy and low incidence of immune-related adverse events. Front Immunol. 2022;13:924542. https://doi.org/10.3389/fimmu.2022.924542.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dali University College of Pharmacy, Dali, China

    Yanqing Yang, Wei Chen, Lixian Dong & Pengfei Gao

  2. The First People’s Hospital of Anning, Kunming, China

    Yanqing Yang, Wei Chen, Lixian Dong & Lian Duan

Authors
  1. Yanqing Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lixian Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lian Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pengfei Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Lian Duan or Pengfei Gao.

Ethics declarations

Conflict of interest

The authors have declared that no conflict interest exists.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 52 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, Y., Chen, W., Dong, L. et al. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis. Clin Transl Oncol (2024). https://doi.org/10.1007/s12094-024-03442-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12094-024-03442-3

Keywords

Search

Navigation